|

Autologous CAR-T cell therapy expressing the BAFF-ligand. Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Luminary Therapeutics1

Indications

  • Multiple Myeloma, Refractory1
  • Multiple Myeloma in Relapse1
  • Cancer1

Cleveland, Ohio1 trial

LMY-920 for Treatment of Relapsed or Refractory Myeloma

University Hospitals Seidman Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.